Nuclear Factor (NF)-kB signaling is important for the maintenance of intestinal immune homeostasis. Inappropriate NF-kB activity results in inflammatory bowel disease (IBD) and thus must be tightly regulated. The ubiquitin-modifying protein A20 (also known as TNFa induced protein 3, TNFAIP3) is a critical regulator of NF-kB signaling as demonstrated by A20-deficient mice which develop spontaneous intestinal inflammation and die perinatally due to spontaneous systemic inflammation and cachexia. Recent genetic studies have identified TNFAIP3 as a candidate gene associated with inflammatory bowel disease. Therefore, an understanding of how A20 regulates intestinal immune homeostasis will be critical in understanding the pathogenesis of IBD and the development of novel therapeutics for patients with IBD. A20 is a unique ubiquitin-modifying enzyme with both deubiquitinating and ubiquitin ligase activity. Preliminary data suggests that A20 is critical in restricting TNF, TLR and NOD signaling and preventing in spontaneous intestinal inflammation and IBD. The proposed research has three specific aims: 1) characterize and define how the A20 ubiquitin modifying domains restrict tumor necrosis factor (TNF) signaling, 2) characterize and define how the A20 ubiquitin modifying domains restrict toll-like receptor (TLR) signaling, and 3) determine how the A20 ubiquitin modifying domains are involved in restricting the development of inflammatory bowel disease in mouse models. These studies will provide mechanistic insight into how A20 restricts inflammatory signaling cascades and regulates intestinal immune homeostasis. These studies will provide potential new leads for the development of novel therapeutics for IBD. The proposed studies will be undertaken with the mentorship of Dr. Averil Ma. A Career Development Plan including didactic courses, research seminars and presentations, and journal clubs has been developed along with a proposed research publication and career timeline. A career development committee of internationally recognized mentors, collaborators, and advisors with expertise in the fields of IBD, immunology, human genetics and apoptosis biology will help ensure that Dr. Lu meets the proposed milestones. The proposed studies will establish a firm foundation for an R01 grant and allow Dr. Lu to become an independent investigator in mucosal immunology and IBD.

Public Health Relevance

Human genetic studies have identified TNFAIP3, which encodes for the protein A20, as a gene associated with inflammatory bowel disease and other autoimmune diseases. In this research proposal, our goals are to understand how A20 regulates the immune system and susceptibility to inflammatory bowel disease and other autoimmune diseases. These studies will provide new insights into the development of targeted therapies for inflammatory bowel disease patients. )

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code